Sutro Biopharma, Inc. (STRO)
16.00
+0.29
(+1.85%)
USD |
NASDAQ |
Sep 25, 16:00
16.00
0.00 (0.00%)
After-Hours: 19:59
Sutro Biopharma Research and Development Expense (Annual) : 166.42M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 166.42M |
| December 31, 2024 | 252.04M |
| December 31, 2023 | 180.42M |
| December 31, 2022 | 137.17M |
| December 31, 2021 | 104.40M |
| Date | Value |
|---|---|
| December 31, 2020 | 76.96M |
| December 31, 2019 | 65.61M |
| December 31, 2018 | 54.26M |
| December 31, 2017 | 51.94M |
| December 31, 2016 | 43.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Upstream Bio, Inc. | 136.81M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |